AbbVie lands FDA approval for next-generation Parkinson’s drug, Juvmo
The US Food and Drug Administration (FDA) has approved AbbVie’s next generation dopamine-based Parkinson’s disease therapy, tavapadon – potentially validating…
28 Sep 2026
Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa
Novo has signed a license agreement with Nanexa to use the Swedish biotech’s longer-lasting drug delivery technology, as the company looks to close the gap to rivals in the cardiometabolic…
28 Sep 2026
Daiichi Sankyo, MSD withdraw cancer drug application
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC)…
28 Sep 2026
Mirum and Incyte’s Atebrioz approved for FOP in US
The US Food and Drug Administration (FDA) has approved Mirum Pharmaceuticals and Incyte’s Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 years and above.…
25 Sep 2026
Aptar Pharma and Macquarie University partner on drug delivery project
Aptar Pharma is collaborating with Macquarie University in a partnership that will see the drug delivery specialist and Australian institution investigate formulation approaches designed to support the pulmonary delivery of…
25 Sep 2026
FDA commissioner nominee affirms MMR vaccine safety despite Trump’s claims
Dr Heidi Overton, Donald Trump’s nominee to lead the US Food and Drug Administration (FDA), has affirmed the safety and effectiveness of the measles, mumps and rubella (MMR) vaccine, contrasting…
25 Sep 2026
Roche and Earendil forge $1.5bn bispecific discovery deal
Roche-owned Genentech has penned a blockbuster deal with Earendil Labs to discover and develop bispecific antibodies for oncology. In exchange for $55m upfront and up to $1.445bn in development, regulatory…